Clonal Evolution including 14q32/IGH translocations in Chronic Lymphocytic Leukemia: analysis of clinicobiologic correlations in 105 patients.
Summary of "Clonal Evolution including 14q32/IGH translocations in Chronic Lymphocytic Leukemia: analysis of clinicobiologic correlations in 105 patients."
Abstract To better define the significance of clonal evolution (CE) including 14q32 translocations involving the immunoglobulin heavy chain gene (IGH) in chronic lymphocytic leukemia (CLL), 105 patients were analyzed sequentially by fluorescence in situ hybridization (FISH) with the following panel of probes: 13q14/D13S25, 11q22/ATM, 17p13/TP53, #12-centromere and 14q32/IGH break-a-part probe. CE was observed in 15/105 patients after 24-170 months (median 64). Recurring aberrations at CE were 14q32/IGH translocation in 7 patients; other aberrations were 17p- 11q-, biallelic 13q-, and 14q32 deletion. CE was detected in 15/58 pre-treated patients; to the contrary none of 47 untreated patients developed CE (p<0.0001). In two cases the appearance of 14q32/IGH translocation was first detected in the bone marrow (BM) or in the lymph node (LN) and 13-58 months later in the peripheral blood (PB). ZAP70+ and high risk cytogenetics predicted for the occurrence of CE with borderline statistical significance (p=0.055 and 0.07, respectively). A shorter time to first treatment (TTT) and time to chemorefractoriness (TTCR) were noted in 15 patients with CE when compared to patients without CE (
TTT:
35 vs 71 months, p=0.0033 and
TTCR:
34 vs 86 months, 0.0046, respectively). Survival after the development of CE was 32 months (standard error 8,5). We arrived at the following conclusions: i) 14q32/IGH translocation may represent one of the most frequent aberrations acquired during the natural history of CLL and, ii) it may be detected earlier in BM or LN samples; iii) CE including 14q32/IGH translocation occur in pre-treated patients with short TTT and TTCR; iii) survival after CE is relatively short.
Affiliation
Journal Details
This article was published in the following journal.
Name: Leukemia & lymphoma
ISSN: 1029-2403
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21767243
- DOI: http://dx.doi.org/10.3109/10428194.2011.606384
Medical and Biotech [MESH] Definitions
Leukemia, Lymphocytic, Chronic, B-cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Leukemia, Prolymphocytic
A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.
Leukemia, Myelogenous, Chronic, Bcr-abl Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Leukemia, Prolymphocytic, T-cell
A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.
Leukemic Infiltration
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
PubMed Articles
Translocations involving MYC are rare in chronic lymphocytic leukemia (CLL), and up to now, their prognostic significance remains unclear. We report the characteristics of 21 patients with CLL and nin...
Reciprocal IGH/14q32 translocations are detectable in 55-70% of patients with plasma cell myeloma; e.g., the adverse t(4;14)(p16;q32) fusing the IGH and FGFR3 genes (immunoglobulin heavy chain/fibrobl...
To better define the significance of proliferation centers (PCs), the morphological hallmark of chronic lymphocytic leukemia (CLL), lymph node biopsies taken from 183 patients were submitted to histop...
The World Health Organization classification uses a cut-off point of 5·0 × 10(9) /l cells with a chronic lymphocytic leukaemia (CLL)-phenotype in peripheral blood to discriminate between monoclo...
Clinical Trials
Chronic lymphocytic leukemia. B-cell chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the Western Hemisphere, accounting for ~25% of all leukemia's. It represents a...
Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation
The purpose of this research study is to collect, freeze and store leukemia cells from the blood or bone marrow of patients that have advanced chronic lymphocytic leukemia (CLL) that is no...
The purpose of the study is to evaluate the ability of Rituximab maintenance therapy to prolong progression free survival in patients with chronic lymphocytic leukemia, who responded to a...
The purpose of this study is to collect a blood sample from patients with Chronic Lymphocytic Leukemia (CLL) and from volunteers without CLL.
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
